Raymond James Financial Inc. Buys New Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Raymond James Financial Inc. bought a new stake in iShares Biotechnology ETF (NASDAQ:IBBFree Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 416,081 shares of the financial services provider’s stock, valued at approximately $55,010,000. Raymond James Financial Inc. owned about 0.89% of iShares Biotechnology ETF as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Huntington National Bank lifted its holdings in iShares Biotechnology ETF by 17.9% in the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock valued at $153,000 after acquiring an additional 160 shares during the period. National Bank of Canada FI lifted its holdings in iShares Biotechnology ETF by 5.9% in the third quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock valued at $600,000 after acquiring an additional 229 shares during the period. IFP Advisors Inc lifted its holdings in iShares Biotechnology ETF by 237.1% in the fourth quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock valued at $2,118,000 after acquiring an additional 11,266 shares during the period. Avior Wealth Management LLC lifted its holdings in iShares Biotechnology ETF by 438.2% in the third quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock valued at $470,000 after acquiring an additional 2,629 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in iShares Biotechnology ETF by 32.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after acquiring an additional 164,000 shares during the period. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Trading Down 0.8 %

Shares of NASDAQ:IBB opened at $135.84 on Tuesday. The company has a market capitalization of $6.42 billion, a PE ratio of 24.52 and a beta of 0.84. The business has a 50 day moving average of $136.08 and a two-hundred day moving average of $140.22. iShares Biotechnology ETF has a 12-month low of $123.60 and a 12-month high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

See Also

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.